Brand names: Ringers
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS Ringer’s Injection is contraindicated in: Neonates (28 days of age or younger) who are receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream [see Warnings and Precautions (5.1) and Specific Populations (8.4) ] . Patients with known hypersensitivity to any components of Ringer’s Injection [see Warnings and Precautions (5.3) ]. Concomitant treatment with ceftriaxone in neonates (28 days of age or younger). ( 4) Patients with known hypersensitivity to Ringer’s Injection. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Exposure to Ringer’s Injection during pregnancy is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with this drug. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
12 interactions on record
Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Calcium administration may increase digoxin effects and lead to toxicity including serious or fatal cardiac arrhythmias. Consider reducing volume or rate of administration.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use may increase renal sodium and lithium clearance, resulting in decreased lithium concentrations. Avoid use; if unavoidable, monitor serum lithium concentrations more frequently.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use increases risk of hypercalcemia. Avoid use; if unavoidable, closely monitor serum calcium concentrations.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use may increase risk of hypernatremia and volume overload. Avoid use; if unavoidable, monitor serum electrolytes, fluid balance, and acid-base balance.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Certain cytotoxic drugs may increase hyponatremia risk. Avoid use; if unavoidable, closely monitor serum sodium concentrations.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use may increase risk of hyponatremia. Avoid use; if unavoidable, closely monitor serum sodium concentrations.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use may increase risk of hypernatremia and volume overload. Avoid use; if unavoidable, monitor serum electrolytes, fluid balance, and acid-base balance.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use may increase risk of hyponatremia. Avoid use; if unavoidable, closely monitor serum sodium concentrations.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Concomitant use increases risk of hypercalcemia. Avoid use; if unavoidable, closely monitor serum calcium concentrations.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride